Literature DB >> 10367847

Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis?

B Djavan1, S Shariat, K Ghawidel, K Güven-Marberger, M Remzi, J Kovarik, W H Hoerl, M Marberger.   

Abstract

OBJECTIVES: The increased incidence of malignancy (ie, prostate cancer) in patients with end-stage renal failure is well known. However, little is known of the impact of hemodialysis and various membrane types on total and free prostate-specific antigen (PSA). We prospectively studied the impact of high- and low-flux dialysis membranes and kidney function on total PSA (tPSA), free PSA (fPSA), and free/total PSA ratio (f/t PSA).
METHODS: A total of 149 men were included. tPSA, fPSA, and f/t PSA were measured before and immediately after dialysis with high-flux (n = 101) and low-flux (n = 48) membranes in the serum and in the dialysis ultrafiltrate. A multivariate analysis of the impact of kidney function and age on the rate of change of all parameters was performed.
RESULTS: Overall, a significant decrease of fPSA (from 0.49 +/- 0.3 to 0.35 +/- 0.3 ng/mL, P <0.0001) and f/t PSA (from 45 +/- 19% to 38 +/- 13%, P <0.0001) and a nonsignificant decrease in serum tPSA were observed. However, fPSA (from 0.51 +/- 0.5 to 0.27 +/- 0.3 ng/mL, P <0.0001) and f/t PSA (from 47 +/- 19% to 31 +/- 18%, P <0.0001) decreased significantly in high-flux membranes only. The ultrafiltrate contained 100% fPSA in high-flux membranes and no fPSA in low-flux membranes. Age, serum creatinine, blood urea nitrogen, and dialysis evaluation parameters (Kt/V) had no impact on correlation with changes in tPSA and fPSA.
CONCLUSIONS: tPSA molecules do not pass high- and low-flux membranes; fPSA passes high-flux membranes only. The nonsignificant decrease of tPSA is due to adsorption to both dialysis membranes. Although tPSA can safely be used to screen patients on dialysis, independently from the dialysis procedure and membrane, fPSA and f/t PSA are only reliable with low-flux membranes. Finally, we can state that the fPSA is most probably cleared through the kidneys by glomerular filtration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10367847     DOI: 10.1016/s0090-4295(99)00010-2

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

Review 1.  [Diagnostics and treatment of prostate cancer after kidney transplantation].

Authors:  A Wicht; A Hamza; H Loertzer; M Dietl; H Heynemann; P Fornara
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

Review 2.  [Urological evaluation and follow-up of the kidney transplant patient].

Authors:  T F Fuller; L Liefeldt; D Dragun; M Tüllmann; S A Loening; M Giessing
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

Review 3.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

Review 4.  Screening for prostate cancer: an update.

Authors:  Shahrokh F Shariat; Peter T Scardino; Hans Lilja
Journal:  Can J Urol       Date:  2008-12       Impact factor: 1.344

5.  Association between percent-free prostate-specific antigen and glomerular filtration rate in transrectal ultrasound-guided biopsy-proven patients with prostate-specific antigen levels ranging from 4 to 10 ng/ml.

Authors:  Jae Heon Kim; Ji Sung Shim; Jae Hyun Bae; Hong Seok Park; Du Geon Moon; Soon-Sun Kwon; Jae Young Park
Journal:  World J Urol       Date:  2013-01-03       Impact factor: 4.226

6.  Screening for prostate cancer using prostate-specific antigen testing in Japanese men on hemodialysis.

Authors:  Toshifumi Kurahashi; Hideaki Miyake; Masashi Shinozaki; Nobutoshi Oka; Atsushi Takenaka; Isao Hara; Yosuke Matsumura; Masato Fujisawa
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

7.  Preventive health care measures before and after start of renal replacement therapy.

Authors:  Wolfgang C Winkelmayer; William Owen; Robert J Glynn; Raisa Levin; Jerry Avorn
Journal:  J Gen Intern Med       Date:  2002-08       Impact factor: 5.128

8.  Increase in percent free prostate-specific antigen in men with chronic kidney disease.

Authors:  Laila Bruun; Caroline Savage; Angel M Cronin; Jonas Hugosson; Hans Lilja; Anders Christensson
Journal:  Nephrol Dial Transplant       Date:  2008-11-21       Impact factor: 5.992

9.  Is incidence of prostate cancer higher in patients with end stage renal disease?

Authors:  Makarand V Khochikar
Journal:  Indian J Urol       Date:  2007-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.